ALZN

Alzamend Neuro, Inc.

Latest Form 4:Purchase$109KbyAULT MILTON C III (Director) · filed Apr 16, 2026

Alzamend Neuro, Inc. (ALZN) has 8 SEC Form 4 filings (18 transaction rows) in the rolling window, disclosed by 3 distinct insiders. Most recent filing: Apr 16, 2026.

The most active filer is Director AULT MILTON C III with 12 filings.

  • Industry:Biotechnology
  • CEO:Stephan Jackman
  • Employees:7
  • HQ:Atlanta, GA, US
  • IPO:2021-06-15

Insider Buying

$109K

reported purchases (SEC code P)

Insider Selling

$1.1M

reported sales (SEC code S)

Unique Insiders

3

in the rolling window

Source
Purchase$109KApr 16SEC ↗
Sale$4KDec 30SEC ↗
Horne William B.First filing
Sale$7KDec 23SEC ↗
Sale$69Oct 24SEC ↗
Sale$247KOct 10SEC ↗
Sale$47KOct 10SEC ↗
Sale$201KOct 8SEC ↗
Sale$143KOct 8SEC ↗
Sale$86KOct 3SEC ↗
Sale$50KOct 3SEC ↗
Sale$161KOct 3SEC ↗
AULT MILTON C IIIFirst filing
Sale$87KSep 30SEC ↗
AULT MILTON C IIIFirst filing
Sale$88KSep 30SEC ↗
AULT MILTON C IIIFirst filing
Sale$8KSep 30SEC ↗

Related companies

Alzamend Neuro, Inc. is in the Healthcare sector.